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Abstract
Background: Age-related alterations in metabolism and excretion of medications increase the risk of adverse
drug events in the elderly. Inappropriate polypharmacy and prescription practice entails increased burdens of
impaired quality of life and drug related morbidity and mortality. The main objective of this trial is to evaluate
effects of a tailored educational intervention towards general practitioners (GPs) aimed at supporting the
implementation of a safer drug prescribing practice for elderly patients ≥ 70 years.
Methods/design: Approximately 80 peer continuing medical education (CME) groups (about 600 GPs) in
southern Norway will be recruited to a cluster randomized trial. Participating groups will be randomized either
to an intervention- or a control group. The control group will not receive any intervention towards prescription
patterns in elderly, but will be the target of an educational intervention for prescription of antibiotics for
respiratory tract infections. A multifaceted intervention has been tailored, where key components are educational
outreach visits to the CME-groups, work-shops, audit and feedback. Prescription Peer Academic Detailers (Rx-
PADs), who are trained GPs, will conduct the educational outreach visits. During these visits, a set of quality
indicators (QIs), i.e. explicit recommendations for safer prescribing for elderly patients, will be presented and
discussed. Software will be handed out for installation in participants' practice computers to enable extraction of
pre-defined prescription data. These data will subsequently be linked to corresponding data from the Norwegian
Prescription Database (NorPD). Individual feedback reports will be sent all participating GPs during and one year
after the intervention. Feedback reports will include QI-scores on individual- and group levels, before and after
the intervention. The main outcome of this trial is the change in proportions of inappropriate prescriptions (QIs)
for elderly patients ≥ 70 years following intervention, compared to baseline levels.
Discussion: Improvement of prescription patterns in medical practice is a challenging task. Evidence suggests that
a thorough evaluation of diagnostic indications for drug treatment in the elderly and/or a reduction of potentially
inappropriate drugs may impose significant clinical benefits. Our hypothesis is that an educational intervention
program will be effective in improving prescribing patterns for elderly patients in GP settings.
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Background
Although appropriate use of drugs may indeed be of vital
importance to elderly patients, drugs represent a double-
edged sword due to their potential adverse effects. Age-
related changes in drug metabolism and sensitivity put
frail elderly patients at particular risk for adverse drug
events (ADEs) [1,2]. The Word Health Organization
(WHO) defines an ADE as a detrimental response to med-
ication that is undesired and unintended, excluding ther-
apeutic failure, poisoning, and intentional overdose [3].
In the elderly, between 10 and 20% of all hospital admis-
sions are drug-related [4-8] and also associated with a
higher mortality than other reasons for hospitalization
[4]. In a comprehensive study from a large internal medi-
cal department in Norway, more than one out of six
deaths were judged to be caused by the drug treatment
used rather than the underlying illness [9]. According to
the WHO, rational use of drugs implicates "each patient
receiving medication appropriate for his/her clinical
needs, in doses meeting the related requirements, for an
adequate period of time and at the lowest cost to them
and to community" [10].
Inappropriate us of drugs commonly occur in the elderly
and may imply impaired quality of life and drug related
morbidity and morbidity [4,11-15]. Problems related to
GPs' lack of updated medication lists for their patients
[16], the common practice of prescribing for patients
without seeing them [17,18], inadequate communication
between physicians and community nurses regarding
treatment for shared care patients [16], and patients' non-
compliance, as well as physicians' lacking ability to under-
stand, detect, and improve compliance, also increase the
risk of medical errors and ADEs [19].
In the Norwegian general practice Møre & Romsdal Pre-
scription study, Straand and Rokstad [15] considered
13.5% of 16774 prescriptions for elderly patients to be
inappropriate. Corresponding figures have been reported
by Stuck et al. [20], who found that 14% of 414 patients
older than 75 years used at least one inappropriate drug.
Willcox et al. [17] found that potentially inappropriate
drugs were prescribed for 23.5% of 6 171 patients 65 years
and older. However, the different studies apply different
criteria for inappropriateness. Based on Beers criteria [20],
Aparasu and Mort [21] reviewed eight studies on prescrip-
tion patterns in elderly, and found that the rate of inap-
propriate drug use varied from 14% in community-
dwelling elderly to 40.3% in nursing home residents.
Prescribing indicators for general practice have been used
for more than two decades [22]. Previous research has
highlighted the importance of a critical approach to pre-
scribing practice [23,24], the defining and assessment of
the appropriateness of prescribing [25,26], the explora-
tion of variations in prescribing across general practices
[27], and the physicians' adherence to various standards
[28]. However, few validated quality indicators exist for
prescribing in general practice [29], and published stand-
ards tend to be consensus-based rather than evidence-
based.
Quality indicators (QIs) are explicitly defined and meas-
urable items which may serve as building blocks in the
assessment of care [30]. As statements about structure,
process, or outcomes they may be used to generate criteria
and standards to measure specific aspects of clinical prac-
tice [31]. Indicators differ from guidelines, review criteria,
and standards and may be regarded as a kind of rules of
the thumb. Primary care rarely meets absolute standards
[32], and the development of indicators must be realistic
and set according to context and patient circumstances
[33]. Indicators can measure the frequency with which an
event occurs, such as prescriptions of a particular drug.
However, indicators do not provide definite answers, they
rather indicate potential problems. Quality measures are
now increasingly being developed for primary care quality
assessments and research [30]. This development has
probably been encouraged by the increased access to large
health care databases, made up by automated electronic
records of e.g. filled prescriptions, professional services,
and hospitalizations [34]. Linking prescription databases
with various electronic patient record (EPR) systems com-
prising detailed information of patients' symptoms, find-
ings and diagnoses enables a "reality-based" pharmaco-
epidemiologic research, which may be useful for high-
lighting areas in need of quality improvements.
The identification of suboptimal practice is, however,
only the first step for quality improvements. Several edu-
cational strategies have been used to improve doctors'
clinical practice, but substantial effects are only rarely
reported [35,36]. Rokstad et al. [37] performed a control-
led educational intervention towards GPs aimed at
improving their prescriptions for acute cystitis and insom-
nia. The intervention included mailed prescription feed-
back along with printed therapeutic recommendations,
and resulted in statistical significant (although clinically
moderate) improvements in prescription patterns in the
intervention group (GPs in one district), compared to the
control group (GPs in another district) [37]. Davies et al.
[38] reviewed 777 continuous medical education (CME)
studies and found evidence that educational intervention
consisting of passive dissemination of clinical practice
guidelines had little or no effect on practice. This corre-
sponds with later reports by Oxman et al. [36] and Free-
mantle et al. [39]. More active strategies, like educational
outreach visits [40,41] and multifaceted interventions
[35], are more effective, but require more resources [35].
In an extensive review, Jamtvedt et al. [41] concluded thatBMC Health Services Research 2006, 6:72 http://www.biomedcentral.com/1472-6963/6/72
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audit and feedback may be effective in improving profes-
sional medical practice, although the effects are generally
moderate, and that absolute effects of audit and feedback
are more likely to be larger when baseline adherence to
recommended practice is low.
Underlying reasons for deviations between clinical prac-
tice and clinical guidelines vary from one problem to
another and from one physician to another [42]. There-
fore, it is recommended to address potential barriers to
change when tailoring an intervention targeting change in
medical performance. Because non-equivalent compari-
son groups may distort the results of evaluations, cluster-
randomized trials (in which healthcare professionals or
groups of professionals, rather than patients are rand-
omized) are more likely to provide valid results than other
research designs, such as controlled before-after or time-
series studies [43].
We have developed an intervention aimed at improving
GPs' prescribing practice for elderly (≥ 70 years) out-
patients, and planned a cluster randomized controlled
trial to assess the effectiveness of this intervention.
Methods
Design
Our hypothesis is that an educational intervention pro-
gram carried out during a 6-month period will be effective
in improving prescribing patterns by reducing the occur-
rence of potentially targeted harmful drugs and drug-drug
interactions in elderly patients.
Our main hypothesis will be tested using a cluster-rand-
omized controlled trial comparing outcomes between the
intervention and control groups at follow-up. Peer contin-
uing medial education (CME) groups of GPs will be rand-
omized to receive a tailored intervention to support a safer
prescription practice for the elderly or to a control group.
The control group will be assigned to another trial,
namely an educational intervention for better prescrip-
tion of antibiotics for respiratory tract infections [44]. As
such, the control group may also be susceptible to changes
in their general prescription patterns, i.e. a possible Haw-
thorne effect. To control for this, we will be able to analyze
prescription patterns for all Norwegian GPs not included
in the current trial, using data from the Norwegian Pre-
scription Database (NorPD), a national registry including
data for all prescription drugs issued at Norwegian phar-
macies, established in 2004 [45].
Prescription data will be collected for all eligible patients
from intervention- and control group GPs at baseline and
one year after the initiation of the trial. Changes in pre-
scribing patterns will be tracked by a set of explicit recom-
mendations (quality indicators) developed by the authors
(Table 1), which will be used to analyze changes in base-
line and post-intervention prescribing patterns. Degree of
improvements will be measured by recording prescrip-
tions of the particular drugs and the concurrent use of
listed drug combinations that the GPs have been recom-
mended to avoid.
Participants
In Norway, specialists in general practice have to renew
their clinical specialty every five years. In this renewal
process, participation in a number of peer CME group
meetings is compulsory, in order to stimulate continu-
ously medical education and reflection. All GPs participat-
ing in such peer groups, on average consisting of six to
eight peers, located in southern Norway, will be invited to
participate in this trial. GPs using one of the four major
EPRs (Infodoc®, WinMed®, ProfDoc Vision® or System X®)
are eligible for the trial. More than nine out of ten Norwe-
gian GPs use one of these systems routinely during con-
sultations with patients [46].
Intervention
The intervention has been developed through a process of
identifying potential harmful prescriptions to elderly;
either as specific drugs and combinations of particular
drugs to be avoided due to clinically relevant interactions,
or the concurrent use of three or more psychotropic drugs.
The identification of suboptimal pharmacological treat-
ments to be targeted in this study, was based on previous
research and active reflection and discussions based on
own clinical experience from general practice. This proc-
ess led to the development of a set of prescription QIs
(Table 1).
In order to implement rational prescribing patterns, 13
GPs will be recruited as tutors, each with responsibility for
the intervention in about three peer groups. Each tutor,
named Prescription Peer Academic Detailer (Rx-PAD),
will receive a four days' pre-study training program, focus-
ing on safety issues in relation to pharmacological treat-
ment in the elderly, pedagogical intervention techniques,
and how to use the data-software for extracting data files
from the EPRs. When recruiting the Rx-PADs, emphasis
will be laid on economic independence from pharmaceu-
tical manufacturers.
The tailored intervention towards the GPs in the peer
CME groups will include two educational outreach visits
by one Rx-PAD, discussions within the peer CME group,
extraction of prescription data, audit and individual feed-
back reports, as well as a one day work-shop with all par-
ticipants, in order to facilitate reflections on personal
prescription patterns. Elements in the tailored interven-
tion are summarized in Figure 1.BMC Health Services Research 2006, 6:72 http://www.biomedcentral.com/1472-6963/6/72
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Table 1: Quality indicators (QIs) for optimal prescription patterns for elderly ≥ 70 years
Quality Indicator Aim Concern
1. Use of an explicit list of regular medications 
when prescribing from the GP's electronic 
medical record.
The share (% of GPs using an explicit list of 
regular medication as default list) should be 
as high as possible.
Suggests that GPs have a more complete 
view of their patients' total regular 
medications.
2. Tricyclic antidepressants:
• Amitryptiline
• Doxepin
• Trimipramine
The share (% of individuals ≥70 years) should 
be as low as possible.
Strong anticholinergic and sedative 
properties increase the risk for impaired 
cognitive functioning in the elderly.
Increased risk for urinary retention (males), 
constipation, impaired vision, and falls and 
fractures.
3. 1st. generation antihistamines:
• Dexchlorpheniramine
• Promethazine
• Alimemazine
• Hydroxycin
The share (% of individuals ≥ 70 years) 
should be as low as possible.
Strong anticholininergic properties. Should 
be avoided in the elderly.
Especially Promethazine and Alimemazine 
may cause extrapyramidal ADEs.
4. 1st. generation (low-potency) antipsychotics:
• Chlorpromazine
• Chlorprotixene
• Levoprometazine
• Prochlorperazine
The share (% of individuals ≥ 70 years) 
should be as low as possible.
Strong anticholinergic and sedative 
properties. May cause extrapyramidal and 
orthostatic ADEs.
Prochlorperazine has no documented effect 
on gait problems in the elderly.
5. Long acting benzodiazepines:
• Nitrazepam
• Flunitrazepam
The share (% of individuals ≥ 70 years) 
should be as low as possible.
Long half-life and risk of accumulation may 
produce prolonged sedation, and cause falls 
and fractures.
6. The muscle relaxant Carisoprodol. The share (% of individuals ≥ 70 years) 
should be as low as possible
Poorly tolerated in elderly patients.
Anticholinergic properties. Sedative and 
relaxing properties, with increased risk of 
falls and fractures.
7. Strong analgesics poorly tolerated by the 
elderly:
• Propoxyphene
• Pethidine
• Opioids with spasmolytics
The share (% of individuals ≥ 70 years) 
should be as low as possible.
Propoxyphene is poorly tolerated by the 
elderly.
Pethidine may cause convulsions and renal 
failure.
Ketobemidone/diphelyldimetylaminobutene 
has anticholinergic properties.
8. Long term oral use of Theofylline The share (% of individuals ≥ 70 years) 
should be as low as possible.
Narrow therapeutic index. Poorly 
documented effect on Chronic Obstructive 
Pulmonary Disease (COPD).
9. Combination of a systemic beta blocking 
agent with an unselective calcium channel 
blocker:
• Verapamil, or:
• Diltiazem
The share (% of individuals ≥ 70 years) 
should be as low as possible.
A nonselective calcium channel blocker in 
combination with a beta blocking agent may 
cause myocardial depression and 
atrioventricular heart block.
10. Combination of NSAID (non-steroid anti-
inflammatory drug) and Warfarin.
The share (% of individuals ≥ 70 years) 
should be as low as possible.
Increased risk for gastrointestinal bleedings 
with or without elevated INR-levels.
11. Combination of NSAID (or a Cox2-
inhibitor) and ACE-inhibitor (or an A2-
blocker).
The share (% of individuals ≥ 70 years) 
should be as low as possible.
May cause kidney failure in elderly patients, 
particularly if presence of general 
arteriosclerosis, dehydration or concurrent 
use of diuretics.
12. Combination of NSAID and SSRI (selective 
serotonin reuptake inhibitors).
The share (% of individuals ≥ 70 years) 
should be as low as possible.
The combination of NSAID and SSRI 
increases the risk of gastrointestinal 
bleeding.
13. Combination of NSAID and diuretics. The share (% of individuals ≥ 70 years) 
should be as low as possible.
May reduce the effect of diuretics and 
worsen existing heart failure.
14. 3 or more psychotropic drugs:
• N02A* Analgesics containing opioids
• N05* Psycholeptics:
1. antipsychotics
2. hypnotics
3. tranquillizers
• N06A* Antidepressants
The share (% of individuals ≥ 70 years) 
receiving three or more different 
psychotropic drugs should be as low as 
possible.
Increased risk for excessive sedation, 
interactions and central nervous adverse 
effects.
Increased risk for falls and fractures.
* Anatomical Therapeutic Chemical (ATC) classification code.BMC Health Services Research 2006, 6:72 http://www.biomedcentral.com/1472-6963/6/72
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Flow of practices through The Rx-PAD Study Figure 1
Flow of practices through The Rx-PAD Study. *Electronic Patient Record, **Norwegian Prescription Database, ***Pre-
scription Peer Academic Detailer
Peer groups in the southern part of 
Norway (n~250) will be invited to 
participate  
Peer groups that 
do not consent to 
participate 
Randomization  
Approximately 1/3 of the peer groups 
recruited to the trial 
Half of recruited peer groups:  
Intervention: Prescription patterns in 
elderly  70 years 
Control: Antibiotics for upper 
respiratory tract infections 
Anticipated loss, due to drop outs and 
withdrawals, estimated to 10% 
Anticipated loss, due to drop outs and 
withdrawals, estimated to 10% 
Half of recruited peer groups:  
Intervention: Antibiotics for upper 
respiratory tract infections
Control: Prescription patterns in elderly 
 70 years
Remaining peer groups in the 
tailored intervention  
Remaining peer groups in the 
tailored intervention  
Retrospective 12 months data collection from 
EPR* and NorPD** 
Retrospective 12 months data collection from 
EPR* and NorPD** 
Intervention in peer groups including 2 visits 
by Rx-PADs***, discussions within the peer 
groups, work-shop, audit and feedback reports 
Intervention in peer groups including 2 visits by 
Rx-PADs***, discussions within the peer groups, 
work-shop, audit and feedback reports 
Retrospective 12 months data collection from 
EPR* and NorPD** 
Retrospective 12 months data collection from 
EPR* and NorPD** 
Analysis of data and preparation of 
manuscripts. Feedback to participating peer 
groups 
Analysis of data and preparation of  
manuscripts. Feedback to participating peer 
groups BMC Health Services Research 2006, 6:72 http://www.biomedcentral.com/1472-6963/6/72
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In the first outreach visit, the main elements of the inter-
vention will be presented, with special emphasis on safer
prescription strategies for elderly (≥ 70 years) out-
patients, choice of first-line drugs, possible harmful effects
of particular drugs, and specific drug combinations to be
avoided. During the visit, a software package will be deliv-
ered to the participating GPs for installation in own prac-
tice computers. This enables data extraction from the
preceding 12-month period, which will comprise baseline
data used in the study. Prescription data will be collected
on diskettes and analyzed by research staff, followed by an
individual prescription report which will be mailed to
each participant.
The second outreach visit, which will take place within
two months after the first one, will focus on the disclosed
individual prescription patterns in relation to the explicit
recommendations provided during the first meeting. The
Rx-PADs will facilitate the discussion within their peer
groups, based on the individual feedback reports, ena-
bling participants to compare own prescription patterns
with overall averages. This will probably trigger discussion
within the peer group, aimed at critical reflection towards
own prescription strategies for elderly patients and facili-
tating disclosure of areas where individual improvements
may be desirable.
About three months after the second outreach visit, all
participants will be gathered in regional work-shops
where rational pharmacological treatment for elderly out-
patients ≥ 70 years will be outlined in more depth, on the
basis of the baseline prescription data.
Twelve months after the first data extraction, a second
data extraction addressing the preceding 12-months pre-
scription patterns, will be made. Each GP will then get a
new feedback report revealing before- and after-interven-
tion-data in relation to the QIs and compared with aver-
age figures for the total sample. Application will be sent to
The Norwegian Medical Association (NMA) to have this
educational intervention approved as a so called "clinical
theme-course", which will give the participants important
CME credit.
Quality indicators (QIs)
In this study we have developed 14 explicit QIs regarding
possible inappropriate prescription patterns to elderly
out-patients ≥ 70 years, based on current knowledge and
pervious research [15,47-52] (Table 1). The face validity
of the QIs will be assessed using a modified three postal
round Delphi consensus technique [47,53,54]. The Del-
phi technique is a structured interactive method involving
repetitive administration of anonymous questionnaires,
usually across two or three postal rounds [30]. There is
limited evidence of the content validity of quality meas-
ures derived using the Delphi technique [53,55]. Still, the
Delphi procedure has been used for validating the rele-
vance of prescribing indicators [29], i.e. concerning GP's
prescribing of non-steroidal anti-inflammatory drugs
[47], as well as indicators for patient and general practi-
tioner perspectives of chronic illness [23], and indicators
for cardiovascular disease [56]. We will recruit a panel of
health professionals (GPs, clinical pharmacologists and
geriatricians; about 20 in each group) to rate the face
validity of our proposed QIs. Also, the participating GPs
will be invited to assess their interpretation of the QIs
used in this study by the end of the six-month educational
intervention. This will be made by filling in a question-
naire where the relevance of each QI may be scored on a
visual-analogue scale.
Data handling
Software aimed at extracting predefined data sets will be
developed for this trial. The software will be compatible
with the four electronic patient record (EPR) systems
(Infodoc®, WinMed®, ProfDoc Vision® or System X®) used
by the waste majority of Norwegian GPs. In addition we
will provide technical telephone support during the
whole data collection period. The participants will get a
deadline for sending their data sets, before they are able to
receive an individual feedback report, and the Rx-PAD
will remind their group to send data sets before the sec-
ond peer group meeting.
Data extraction will provide information on contacts with
patients and prescriptions issued. Prescription data will be
described in terms of The Anatomical, Therapeutic,
Chemical (ATC) classification system with Defined Daily
Doses (DDDs), in short: the ATC/DDD system [57].
In order to merge prescription data provided by NorPD
with data from the EPR systems, the Civil Personal Regis-
tration (CPR) number for each patient will be extracted
from the EPR. These are the unique identification num-
bers for Norwegian citizens, and will be deleted from the
research database after the record linkage has been per-
formed. The dataset from NorPD will provide data on
drugs actually dispensed.
Extracted data from the EPR will be encrypted, stored on a
diskette and mailed to the principal researcher. A flow-
chart of the data collection is summarized in Figure 2.
Outcome measures
Primary outcome measures will be changes in prescrip-
tion patterns after the tailored educational intervention
regarding the listed QIs (Table 1). Post-intervention pre-
scription data will be collected one year after the collec-
tion of the baseline prescription data. Prescription
patterns in the intervention group will be compared withBMC Health Services Research 2006, 6:72 http://www.biomedcentral.com/1472-6963/6/72
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the non-intervention control group, and with correspond-
ing data (from NorPD) based on a random sample of
Norwegian GPs not included in the current trial.
In addition to investigating changes in each QI, we will
summarize changes for all QIs (Table 1), in order to give
a total sum score for improvement potentials. The differ-
ence in total QI sum score between the intervention group
and the control group will be a main outcome measure.
The QI regarding regular use of the EPR function showing
patient's total regular medications will not be included in
this sum score. Outcome measures are summarized in
Table 2.
It would also be interesting to investigate if this interven-
tion may influence all-over mortality patterns for elderly
patients targeted during this intervention as compared to
corresponding elderly patients in the control group [44].
By 2006, death data are not yet included in the NorPD,
but efforts are currently undertaken to include such data
in the NorPD on a regular basis. A possible mortality
study has not yet been elaborated in details, but this will
be considered.
Recruitment and randomization
Block-randomization of peer groups will be done within
geographical strata, each comprised of one or more coun-
ties. The size of the blocks will vary according to the
number of recruited groups within each stratum. An inde-
pendent researcher not involved in the study will be
responsible for the randomization. Based on this rand-
omization, peer CME groups will be assigned to either the
intervention group or the control group.
Pilot study
With the exception of the one-day CME-course, the inter-
vention will be piloted in one CME group before the main
trial.
Ethics and data security
Physicians participating in the peer CME groups will be
given information about the objectives of the study and
the practical implications this may have on their practice.
They will be told that each peer CME group will be rand-
omized to one out of two interventions (improved pre-
scription patterns towards elderly ≥ 70 years, or improved
antibiotic prescriptions for respiratory tract infections),
and that they will serve as control-group for the interven-
tion they do not take part in. Participation and data extrac-
tion are based on written, informed consent from all
physicians. The aim of this study is improved quality
according to well established principles for good clinical
practice and should therefore not imply risks for the
patients involved, and we find it unlikely that the current
intervention might worsen the quality of care. The project
has been presented for The Regional Committee for
Research Ethics and approval from The Norwegian Social
Science Data Services (NSD) has been obtained, implicat-
ing acceptance to extract prescription data. We have
assessed the risk for misusing the collected data, and
found this unlikely due the fact that the data are linked to
de-identified ID numbers. In order to use patient identifi-
cation data in the record linkage of the NorPD and EPR
databases, The Norwegian Directorate for Health and
Social Affairs have approved a dispensation from the
Health-Professional Secrecy regulations.
Sample size and statistics
In a pilot study (including 13 physicians) for the present
study, the mean number of positive hits on our listed QIs
(Table 1) made up 25 hits per 100 elderly patients during
the preceding 12 months period. In accordance with this
finding, we anticipate an occurrence of inappropriate pre-
scription of about 25 hits per 100 elderly patients in the
present study.
Proving a clinical relevant reduction from 25 to 17 hits or
less per 100 patients (32% relative reduction), assuming
that the prevalence of inappropriate prescriptions in the
Logistics of data collection Figure 2
Logistics of data collection. Flow-chart of merging proc-
ess of prescription data provided by the Norwegian Prescrip-
tion Database (NorPD) and data from the electronic patient 
record (EPR) systems. Patients' Civil Personal Registration 
(CPR) numbers are unique Norwegian residents' identifica-
tion keys. Health Personnel Registration (HPR) numbers are 
unique Norwegian health personnel registration keys. Identi-
fiable data will be deleted from the research database when 
the merge is completed, as the de-identified personal IDs will 
be sufficient for the subsequent data analysis. Statistics Nor-
way, which is the public institution in Norway responsible for 
collecting, analyzing and disseminating official statistics, will 
provide CPR and HPR pseudonyms making it possible to 
merge the two data sources.
Data flowchart
Participant’s
EPR system Statistics Norway
Norwegian Prescription
Database - NorPD
(Pseudonymous) 
Project site
University of Oslo
Project IDs linked to patients’ CPR 
number and doctors’ HPR 
numbers
Project ID’s linked to 
pseudonymous CPR and 
HPR numbers 
Patients’ data linked to 
project IDs (de-identified 
personal IDs) 
Prescription data linked to 
Project IDsBMC Health Services Research 2006, 6:72 http://www.biomedcentral.com/1472-6963/6/72
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control group remains constant, will imply a need for 74
peer groups in total (power of 80%; statistical significance
level of 5%). This estimation takes into account the need
to adjust for intra-cluster correlation, since data within the
peer CME groups cannot be assumed to be independent.
Furthermore, we assume the average number of GPs per
peer CME group to be 7 (allowing for some withdrawals)
and that the average number of patients ≥ 70 years per
participating GP during the study period will be 165.
Based on previous studies [46,58], the intracluster correla-
tion coefficient is assumed to be 0.085, resulting in a var-
iance inflation factor of 99 [59].
We will carry out post-test comparisons between the inter-
vention and control group using cluster-adjusted chi-
square and t-tests. Analysis of covariance may be used to
adjust for imbalance of baseline levels between the inter-
vention- and control-groups [60]. The data set will prima-
rily be analyzed according to the cluster randomization,
however, analyzes at physician- and sub-groups of physi-
cians as well as compared to NorPD-data for GPs not par-
ticipating in the study, will also be performed.
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